GLP-1 medications have transformed how weight loss and management are being treated—and beginning July 1, 2026, there will be a major shift in how Medicare pays for them.
The Centers for Medicare & Medicaid Services (CMS) has launched the Medicare GLP-1 Bridge Program, a time-limited demonstration program allowing eligible Medicare Part D beneficiaries to access certain GLP-1 weight-loss medications for just $50 per month.
This program creates a real opportunity for independent pharmacies. More patients at your counter will be asking about it—and the more you know, the better positioned you are to help them navigate it and keep their prescriptions at your pharmacy.
Here's what you need to know before the first claims start rolling in:
The Medicare GLP-1 Bridge Program is a short-term CMS demonstration program running from July 1, 2026 through December 31, 2027. It was designed to give eligible Medicare Part D beneficiaries early access to GLP-1 medications for weight loss while CMS works toward a longer-term solution under the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health).
GLP-1 drugs for weight loss were previously excluded from Medicare Part D coverage. As such, the Bridge Program marks the first time Medicare has systematically covered these medications for weight loss.
The Bridge Program operates outside of the standard Medicare Part D benefit, which means your patients' existing Part D plans are not directly involved in managing or processing these claims.
Instead, CMS has contracted a single central processor—Humana—to handle prior authorizations, claims adjudication, and pharmacy payments nationwide.
The program is available in all 50 states and U.S. territories.
Three GLP-1 medications are covered under the Medicare GLP-1 Bridge (for weight management only):
Importantly, Ozempic® and Mounjaro® are not covered under the Bridge Program.
Patients must be enrolled in a standalone Medicare Part D Prescription Drug Plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD) in 2026. This includes beneficiaries in Special Needs Plans (SNPs) and employer/union group waiver plans (EGWPs).
Beneficiary is:
Patients are NOT eligible for the Bridge Program if they are already receiving a GLP-1 through their standard Part D plan for a covered indication— such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH (metabolic dysfunction-associated steatohepatitis).
The Bridge Program is specifically for patients seeking GLP-1 coverage for weight loss who would not otherwise have that coverage.
Upon receipt of an eligible prescription, your pharmacy will submit a claim to the Medicare GLP-1 Bridge processor (BIN: 028918 | PCN: MEDDGLP1BR) using the beneficiary’s Medicare Beneficiary Identifier (MBI), or Medicare Number on their red, white, and blue card, as the ID.
If the claim is denied, your pharmacy may start the PA process as you normally do.
Note: The claim should not be routed to the patients’ regular Medicare Part D plan as it will not be covered.
The prescribing provider will then review and submit the prior authorization request to Humana (the CMS central processor).
Prescribers are also required to attest that the patient is receiving counseling on lifestyle modifications, including structured nutrition and physical activity, consistent with the FDA-approved label.
Once the PA is approved, patients can fill their prescription at any participating pharmacy, without any additional enrollment or opt-in on your part.
You don't need to opt in. Pharmacies may automatically participate in the Medicare GLP-1 Bridge. No separate enrollment is required.
Collect a $50 copay. Every patient who fills a Bridge-covered GLP-1 will owe a flat $50 copay per fill, regardless of where they are in their Part D benefit phases. Low-income subsidy (LIS/Extra Help) protections do not apply to this copay, and it does not count toward the standard Part D out-of-pocket limit.
Reimbursement is at WAC. Pharmacies are reimbursed at the wholesale acquisition cost (WAC) of the drug on the date of service, minus the $50 copay, plus a dispensing fee, and applicable sales tax. The dispensing fee is $3 per claim (or $5 per claim for long-term care patients). CMS has negotiated a net price of $245 per monthly supply directly with manufacturers — the difference between WAC and that net price is recouped through manufacturer rebates, not from the pharmacy.
For many of your Medicare patients who have been curious about GLP-1 medications for weight loss, this program marks new territory. You may be the first healthcare professional to explain it to them clearly.
Here's a quick cheat sheet for patient conversations:
RedSail is committed to helping pharmacies stay ahead of the curve. Bridge Program opportunities are coming soon to the Clinical+ portal. With these campaigns, we can help you identify patients who may be eligible and provide guidance to help your staff along the way.
The Medicare GLP-1 Bridge marks a historic shift in how weight management is covered for Medicare patients—and it places pharmacies at the center of access
CMS is continuing to release operational guidance, and detailed pharmacy claims processing instructions are expected prior to launch.
For the most current program information, visit the official CMS Medicare GLP-1 Bridge Program page.
